Wall Street brokerages expect that Aratana Therapeutics Inc (NASDAQ:PETX) will announce sales of $5.70 million for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Aratana Therapeutics’ earnings, with the highest sales estimate coming in at $6.20 million and the lowest estimate coming in at $5.20 million. Aratana Therapeutics reported sales of $6.16 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 7.5%. The business is expected to announce its next quarterly earnings results on Thursday, November 1st.
On average, analysts expect that Aratana Therapeutics will report full year sales of $26.80 million for the current financial year, with estimates ranging from $20.50 million to $38.10 million. For the next financial year, analysts expect that the company will post sales of $47.57 million per share, with estimates ranging from $40.10 million to $52.60 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Aratana Therapeutics.
Aratana Therapeutics (NASDAQ:PETX) last posted its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.05. Aratana Therapeutics had a negative net margin of 154.23% and a negative return on equity of 35.25%. The company had revenue of $4.91 million during the quarter, compared to the consensus estimate of $4.72 million.
Shares of NASDAQ PETX traded up $0.06 on Friday, reaching $5.14. 211,201 shares of the company traded hands, compared to its average volume of 250,932. Aratana Therapeutics has a fifty-two week low of $3.67 and a fifty-two week high of $7.28. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.02 and a quick ratio of 2.82. The company has a market cap of $241.69 million, a P/E ratio of -5.29 and a beta of 2.78.
In other Aratana Therapeutics news, insider Peter Steven St sold 11,513 shares of the company’s stock in a transaction that occurred on Monday, July 30th. The stock was sold at an average price of $4.33, for a total value of $49,851.29. Following the completion of the transaction, the insider now owns 649,233 shares in the company, valued at approximately $2,811,178.89. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Brent Standridge sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, June 25th. The stock was sold at an average price of $4.56, for a total value of $45,600.00. Following the completion of the transaction, the chief operating officer now owns 99,967 shares of the company’s stock, valued at approximately $455,849.52. The disclosure for this sale can be found here. Insiders have sold a total of 28,815 shares of company stock valued at $133,057 in the last quarter. Company insiders own 5.30% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PETX. MetLife Investment Advisors LLC purchased a new position in Aratana Therapeutics in the 4th quarter worth approximately $110,000. American Century Companies Inc. purchased a new position in Aratana Therapeutics in the 2nd quarter worth approximately $195,000. Goldman Sachs Group Inc. raised its position in shares of Aratana Therapeutics by 35.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 68,039 shares of the biopharmaceutical company’s stock valued at $358,000 after acquiring an additional 17,677 shares in the last quarter. Jane Street Group LLC raised its position in shares of Aratana Therapeutics by 683.0% during the 1st quarter. Jane Street Group LLC now owns 81,952 shares of the biopharmaceutical company’s stock valued at $361,000 after acquiring an additional 71,486 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. raised its position in shares of Aratana Therapeutics by 23.8% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 90,100 shares of the biopharmaceutical company’s stock valued at $398,000 after acquiring an additional 17,300 shares in the last quarter. Hedge funds and other institutional investors own 67.82% of the company’s stock.
Aratana Therapeutics Company Profile
Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.
Further Reading: Are Wall Street analysts’ stock ratings worth following?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.